INTRODUCTION
Many methods have been proposed for the partial purification of antihemophilic factor (factor VIII) from human plasma. Recently, we described a technique in which this clot-promoting agent was separated from cryoprecipitates of normal plasma by precipitation with concanavalin A, a globulin derived from jack beans (1) . The purification achieved was approximately 350-to Dr. Ratnoff is a Career Investigator of the American Heart Association.
Received for publication 18 November 1968 and in revised form 31 December 1968. 800-fold compared with the plasma from which the fractions were separated. Its precipitation by concanavalin A implied that antihemophilic factor is a glycoprotein, and its behavior on ultracentrifugation, gel filtration, and disc electrophoresis suggested that its mol wt is greater than two million. Whether the great molecular size of antihemophilic factor is due to aggregation of smaller units during its separation from plasma in the cold could not be determined.
The present report outlines a much simpler method for separating small amounts of antihemophilic factor by utilizing agarose gel filtration, a step previously used by Johnson (2), Hershgold (3) and their associates. The specific activity of the purest fractions, prepared from chylomicron-poor human plasma, averaged 67 units/mg of protein and represented purification, compared to the plasmas from which they were separated, as high as 6300-fold. Evidence was obtained that the molecular weight of antihemophilic factor, as it exists in freshly drawn plasma, is indeed probably greater than two million.
METHODS
Citrated plasma was prepared from venous blood to which 1/9 volume of sodium citrate buffer (pH 5.0, 0.13 M with respect to citrate) had been added. The blood was obtained from normal individuals, from patients with classic hemophilia (factor VIII deficiency) or von Willebrand's disease, and from a patient with a circulating anticoagulant directed against antihemophilic factor, first noted post partum. In some experiments, normal donors exercised for 10 min before venepuncture to increase the concentration of antihemophilic factor in blood.
Casual samples of plasma were prepared, without attention to the subjects' diet, by 20C . In others, the citrate buffer was prewarmed to 37'C, and centrifugation was carried out at room temperature for 10 min in warmed steel centrifuge cups filled with water heated to 370C. The supernatant plasmas were transferred to silicone-coated Lusteroid tubes and used immediately.
Chylomicron-rich plasma from the blood of subjects who had ingested a fatty meal of their own choosing within 3 hr before venepuncture, was prepared with uncoated syringes and uncoated polypropylene centrifuge cups to avoid admixture of silicone oil and the plasma. The plasma was separated by centrifugation at 3500 rpm for 15 min at 2'C, transferred to uoncoated polypropylene tubes, and used immediately.
Chylomicron-poor plasma from the blood of subjects who had ingested no fat other than that in bread or dry cereal since the preceding evening meal, was prepared with uncoated syringes and centrifuge tubes. The plasma was separated by centrifugation at 16,000 rpm for 10 min at 2'C, transferred (with care to avoid the uppermost layer of plasma) to uncoated polypropylene tubes, and used immediately.
Cryoprecipitates of normal human plasma, prepared essentially by the method of Pool and her associates (4) Gel filtration through columns 0.9 cm in diameter was performed at 4 or 37°C by applying 2.5 ml of fresh plasma and eluting with buffer at a pressure of 50 to 60 cm above the outlet of the column. The effluent was collected in 1.0 ml aliquots and assayed immediately for antihemophilic activity and total protein (1) . Gel filtration through columns 2.5 X 36 cm in size was carried out at 4°C by applying 5 ml of fresh plasma or the entire volume of a cryoprecipitate and eluting with buffer at a pressure of 80 to 120 cm above the outlet of the column; the effluent was collected in 2.0-ml aliquots. The 
RESULTS
Filtration of casual samples of normal plasma at 40C. When normal plasma was filtered through agarose at 4VC, antihemophilic activity appeared in fractions close to the void volume of the columns, whether these were 0.9 X 33 cm or 2.5 X 36 cm in size. Antihemophilic activity was not detected at any other point in the elution pattern. The peak of antihemophilic activity coincided with a small protein peak, which emerged from the columns at a point preceding that at which porcine thyroglobulin was eluted. Aliquots with the highest antihemophilic activity were tested for the presence of other clotting factors. None contained coagulable protein or plasminogen, as measured by the techniques described, but these techniques were not sensitive to concentrations of fibrinogen below about 20 pug/ml. PTA (factor XI) was present at concentrations as high as 5% that of the filtered plasma, and at least some of this appeared to be activated. Traces (< 1%) of Hageman factor (factor XII) and proaccelerin (factor V) were also detected.
8-Lipoprotein could not be demonstrated immunologi-
cally. In 12 experiments, the purification achieved by fractionation of casual samples of plasma was 320-to 2000-fold, averaging 1500-fold, and the specific activity of the antihemophilic factor in the purest fractions of each experiment ranged from 2.9 to 47 units per mg of protein, averaging 18 units/mg. From 20 to 66% of the antihemophilic factor of the filtered plasma was recovered in a volume of 3-20 ml, the average recovery being about 40%; the purification of such pools was slightly less than that in the tube with highest specific activity. Similar results were obtained by filtering plasma through columns of agarose 0.9 X 56 cm in size at 40C.
Filtration of chylomicron-rich and chylomicron-poor samples of normal plasma at 40C. A chance observation suggested that the purity of antihemophilic factor was a function of the chylomicron content of the plasma tested. Blood was drawn from three normal subjects within 3 hr after they had ingested a fatty breakfast, and the plasma separated at relatively low centrifugal force (2750 g). (Fig. 1) and separating the plasma at relative high centrifugal force (31,000 g). Now the void volume contained antihemophilic activity of much greater purity.
The specific activity varied from 11 to 228 units/mg of protein, averaging 67 units/mg, and the degree of purification achieved was 350-to 6300-fold, averaging 3360-fold. After 5 ml of plasma was applied to the column, about 50% of the total activity could be recovered in a volume of 8-14 ml, but the purity achieved by pooling active fractions was slightly less than that of the tubes with the greatest specific activity. The purest fractions contained PTA at a concentration about 2% that of the plasma that was filtered, as well as traces (< 0.1%) of Christmas factor (factor IX) and Hageman factor, but none of the other factors tested was detected. Lipid analysis of filtrates of three chylomicron-poor plasmas showed phospholipids as the dominant components with smaller amounts of triglycerides. The presence of highly nonpolar compounds was also observed. The total lipid content of these filtrates seemed grossly smaller than those obtained from chylomicron-rich plasmas.
Filtration of normal plasma at 370C. The experiments described do not tell us whether antihemophilic factor, as it exists in plasma, is a macromolecule, or whether it aggregates when exposed to the cold temperatures used during centrifugation and filtration. To test this, plasma was prepared by centrifuging fresh citrated blood at or near 370C, and then filtered through columns of agarose, 0.9 X 56 cm, at 370C. In three such experiments, antihemophilic factor activity appeared at the void volume; the filtrates contained 12.5-16 units of antihemophilic factor/mg of protein. These experiments are evidence that the large molecular size of antihemophilic factor is not an artefact induced by exposure to cold.
The identity of antihemophilic factor. The clot-promoting activity of the fractions of plasma filtered with the void volume was attributed to their content of antihemophilic factor because they corrected the coagulative defect of hemophilic plasma. To corroborate this interpretation, fraction rich in antihemophilic factor were incubated with plasma containing a circulating anticoagulant directed against this substance. The antihemophilic activity of the filtered fractions was inactivated by this procedure (Table I ). This observation confirms the view that the clot-promoting material in the filtered fraction was antihemophilic factor.
Ultracentrifugation of plasma and purified antihemophilic factor. Normal plasma was subjected to ultracentrifugation for 3 hr in gradients of 5-20% sucrose. responding approximately to the peak optical density of 40S subribosomal particles (Fig. 2) . As anticipated, the bulk of protein was in those samples from the top of the centrifuge tube. A similar result was obtained by centrifuging a fraction rich in antihemophilic factor, obtained by gel filtration of plasma, but only traces of activity were recovered, apparently because of its instability. Filtration of hemophilic plasma. Chylomicron-poor plasma was prepared from the venous blood of five patients with classic hemophilia, none related to the other. In each instance, when the plasma was filtered through agarose columns (2.5 X 36 cm, at 4VC) a small peak of protein was noted in tubes corresponding to those which would have contained antihemophilic factor, had normal plasma been filtered. The protein content of these peaks ranged from 1.3 to 5 ug/ml, averaging 3.5 ttg/ml. In contrast, the protein content of the tubes with highest specific activity in the 15 experiments with chylomicronpoor normal plasma, filtered at 4VC, ranged from 1 to 31 /Ag/ml, averaging 8.4 ug/ml. Notably, the protein content was 5 jug or less in four fractions obtained from normal plasma. Lipid analysis of the tubes of one fasting individual showed the features of fasting normal plasmas, with phospholipids the dominant component and smaller amounts of triglycerides present. In addition, traces of free cholesterol and cholesterol esters were detected. Highly nonpolar compounds were also detectable.
Similar results were obtained by filtering the chylomicron-poor plasma of two unrelated patients who had von Willebrand's disease. The antihemophilic activity of the tube with peak activity was less than 0.01 unit/ml in one case, and about 0.1 unit/ml in the other; the protein content was 3 and 4 pg/ml, respectively.
Chylomicron-poor plasma of a patient with a circulating anticoagulant directed against antihemophilic fac- * 0.6 ml of gel-filtered antihemophilic factor, in barbitalsaline buffer, was incubated at 370C with 0.6 ml of buffer or 0.6 ml of the plasma of a patient with a circulatory anticoagulant, diluted 1:4 with buffer. At intervals, 0.1 ml aliquots were diluted 10-fold with buffer and assayed for antihemophilic activity, and compared with the activity of nonincubated antihemophilic factor, diluted serially with buffer. tor was also filtered through agarose. TI responding to that which contained peak an activity when normal plasma was filtered column was devoid of clot-promoting activi tained 5 ,ug of protein/ml. These highly purified preparations could be obtained ie tube cor-only if the plasma was chylomicron-poor. Lesser purifiitihemophilic cation was achieved from blood obtained at random or through the after the ingestion of a fatty meal; under these condiity, and con-tions, the fractions filtered at the void volume were turbid as if rich in chylomicrons. Even those specimens predlasma. The pared from chylomicron-poor plasma contained traces of iermit purifi-lipids. No distinct difference was noted between the experiments, lipid pattern of tubes rich in antihemophilic factor and *om cryopre-the corresponding tubes prepared from the plasma of a 1 at 40C. In hemophiliac; in this comparison, the normal and hemohe antihemo-philic plasmas were chylomicron-poor. No evidence has ared, but the as yet been found that the lipid in the antihemophilic s of filtrate, preparation was anything except a contaminant. ing 10 units/ There is every expectation that further purification of zd because it antihemophilic factor can be achieved. Small amounts of to the pres-protein-less, on the average, than that found when norcryoprecipi-mal plasma was filtered-appeared near the void volume cryoprecipi-upon filtration of plasma from patients with classic he-,appointing-mophilia, von Willebrand's disease. or a circulating anticoagulant directed against antihemophilic factor; Gel-filtered the data were insufficient to determine whether the dif- Gel-Filtered Antihemophilic Factor be judged from earlier studies of Hurt, Wagner, and Brinkhous (9) who precipitated antihemophilic factor from human plasma by adding p-alanine, and then removed part of contaminating fibrinogen by adsorption with bentonite. Although their products were 5000-fold purified, at least half of the protein in their material was fibrinogen. In agreement with this, Johnson and his associates (2) prepared antihemophilic factor approximately 10,000-fold purified (164 units/mg of protein) by filtration of a partially purified antihemophilic factor preparation through agarose or by sucrose gradient ultracentrifugation.
In an earlier study, antihemophilic factor, separated by precipitation by concanavalin A, appeared to have a mol wt greater than two million. A similar estimate may be made from data described in the present report, in which antihemophilic activity was excluded from agarose columns and was found in ultracentrifugal fractions corresponding to those containing 40S subribosomal particles. The possibility existed that the high molecular weight of our antihemophilic factor was caused by aggregation of smaller units by the cold temperatures to which the plasma was exposed. When antihemophilic factor was separated by gel filtration at 370C, however, it appeared at the void volume. Although we cannot exclude the possibility that additional aggregation occurred in the cold, a minimal mol wt of two million remains the best estimate.
Studies of antihemophilic factor have been plagued by the instability of this protein. Lyophilization of purified antihemophilic factor in the presence of 1% gelatin has provided some degree of stabilization. Since this protein can be injected intravenously, its use may have pragmatic significance.
The question arises whether the technique described in this report can be adapted for clinical use. Conceivably, antihemophilic factor filtered through Sepharose 4B may be toxic. Moreover, to be economically feasible, methods used to purify antihemophilic factor should allow for the use of the rest of plasma. Our attempts to separate antihemophilic factor from cryoprecipitates were marred by erratic recoveries. Preliminary experiments suggest that gel filtration of Cohn fraction I of plasma may provide highly purified antihemophilic factor, and yet allow utilization of the remaining Cohn fractions,1 as previously suggested by Johnson (2) .
